Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Equivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Next Previous
Trial Profile

Equivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric pyrophosphate (Primary) ; Ferric pyrophosphate (Primary)
  • Indications Iron metabolism disorders
  • Focus Pharmacokinetics; Registrational
  • Sponsors Rockwell Medical Technologies

    • Most Recent Events

    • 07 Nov 2021 Results published in the Journal of Clinical Pharmacology
    • 27 Mar 2020 According to a Rockwell Medical India media release, the U.S. Food and Drug Administration (FDA) has approved New Drug Application (NDA) for its Intravenous (I.V.) formulation of TRIFERIC.
    • 06 Aug 2019 According to a Rockwell Medical Technologies media release, based on the results of this study, the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for its Intravenous (I.V.) formulation of TRIFERIC with a PDUFA (Prescription Drug User Fee Act) date of March 28, 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top